A new FDA-approved blood test offers adults another way to screen for colorectal cancer, making early detection easier with a routine blood draw.
- The FDA approved SimpleScreen CRC, a blood test for colorectal cancer screening in average-risk adults aged 45 years and older
- The test uses AI and cell-free DNA analysis to detect cancer-related molecular signals from a routine blood sample
- Experts say it complements—but does not replace—colonoscopy, which remains the gold standard for screening
A simple blood test has become the latest option for colorectal cancer screening after receiving approval from the U.S. Food and Drug Administration (FDA).
Developed by Freenome and commercialized in the United States by Abbott, SimpleScreen™ CRC is designed to detect molecular signals linked to colorectal cancer and certain advanced precancerous growths through a routine blood sample (1✔ ✔Trusted Source
FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
).
According to the U.S. FDA and Freenome, the test is intended for adults aged 45 years and older who are at average risk of colorectal cancer.
Unlike stool-based tests or colonoscopy, this screening method requires only a blood draw, offering another option for people who avoid or delay recommended screening.
However, experts emphasize that it is not a replacement for colonoscopy, particularly because colonoscopy remains the most effective method for detecting and removing precancerous polyps.
According to the American Cancer Society (ACS), choosing any recommended screening test is better than skipping screening altogether (2✔ ✔Trusted Source
Colorectal Cancer Screening Tests
Advertisement
Why Is the New SimpleScreen CRC Blood Test Making Headlines?
The FDA approval of SimpleScreen CRC marks an important step in colorectal cancer screening because it offers eligible adults a simple blood test instead of stool-based screening or an invasive procedure.
According to Freenome, the test is designed for adults aged 45 years and older who are at average risk of colorectal cancer.
Advertisement
Overview of the FDA-Approved SimpleScreen CRC Blood Test
| Screening Parameter | SimpleScreen CRC |
|---|---|
| Primary Purpose | Screens for colorectal cancer (CRC) and certain advanced precancerous lesions before symptoms develop. |
| Type of Test | Non-invasive blood-based screening test. |
| Target Population | Adults aged 45 years and older who are at average risk of colorectal cancer. |
| Developer | Freenome. |
| Commercialization (U.S.) | Abbott. |
| Sample Collection | Two tubes of blood collected during a routine blood draw. |
| Detection Technology | Analyses circulating cell-free DNA (cfDNA) and DNA methylation changes associated with colorectal cancer. |
| Artificial Intelligence Role | A proprietary machine-learning algorithm analyses molecular patterns to identify cancer-related signals. |
| Testing Laboratory | Samples are processed at Freenome’s CLIA-certified laboratory. |
| Turnaround Time | Approximately two weeks. |
| Clinical Role | An additional screening option for eligible adults; positive results require follow-up colonoscopy. |
Advertisement
How Can a Simple Blood Sample Spot Hidden Signs of Colorectal Cancer?
Unlike a colonoscopy, SimpleScreen CRC does not examine the colon directly. The test searches for tiny fragments of cell-free DNA (cfDNA) released into the bloodstream by normal and abnormal cells.
It then uses artificial intelligence to identify DNA methylation patterns that may indicate colorectal cancer or certain advanced precancerous lesions.
The screening process involves just a few simple steps:
- A healthcare provider collects two tubes of blood.
- The sample is sent to Freenome’s CLIA-certified laboratory.
- Scientists isolate cell-free DNA (cfDNA) from the blood plasma.
- The test analyses DNA methylation patterns linked to colorectal cancer and advanced precancerous lesions.
- An AI-powered machine-learning algorithm evaluates these molecular signals.
- Test results are typically available within about two weeks.
The convenience of a routine blood draw may encourage more eligible adults to participate in colorectal cancer screening, particularly those who are hesitant to undergo colonoscopy or stool-based tests.
How Well Did the Blood Test Perform in the Largest Clinical Trial?
The FDA approval was supported by findings from the PREEMPT CRC study, the largest clinical validation study conducted for a blood-based colorectal cancer screening test.
According to the JAMA study, researchers enrolled nearly 49,000 average-risk adults between 45 and 85 years of age across 201 clinical sites in the United States (3✔ ✔Trusted Source
Clinical Validation of a Circulating Tumor DNA-Based Blood Test to Screen for Colorectal Cancer
The study evaluated how effectively the blood test could detect colorectal cancer while minimizing false-positive results.
PREEMPT CRC Trial: From Study Design to FDA Approval
| Study Component | Findings | Why It Matters |
|---|---|---|
| Clinical Trial | PREEMPT CRC | Largest validation study for a blood-based colorectal cancer screening test. |
| Published In | JAMA | Peer-reviewed clinical evidence supporting FDA approval. |
| Participants Enrolled | 48,995 adults | Large study population strengthens confidence in findings. |
| Participants Analysed | 27,010 average-risk adults | Final group used to evaluate test performance. |
| Age Group Studied | 45–85 years | Matches the intended screening population. |
| Clinical Sites | 201 centres across the U.S. | Demonstrates performance across diverse healthcare settings. |
Can the New Blood Test Replace a Colonoscopy? Here’s What Experts Say
While SimpleScreen CRC makes colorectal cancer screening easier, it is not a substitute for colonoscopy. Colonoscopy remains the gold standard because it not only detects cancer but can also remove precancerous polyps before they become cancerous.
The two screening methods serve different purposes, as shown below.
SimpleScreen CRC Blood Test vs. Colonoscopy: What’s the Difference?
| Screening Aspect | SimpleScreen CRC Blood Test | Colonoscopy |
|---|---|---|
| Primary Purpose | Screens for colorectal cancer and some advanced precancerous lesions. | Detects colorectal cancer and precancerous polyps while allowing immediate treatment. |
| How the Test Is Performed | Routine blood draw. | A flexible camera examines the entire colon. |
| Ability to Detect Colorectal Cancer | High. | Very high. |
| Ability to Detect Advanced Precancerous Lesions | Lower than colonoscopy. | High. |
| Can Precancerous Polyps Be Removed? | No. | Yes, during the same procedure. |
| Bowel Preparation Required | No. | Yes. |
| Sedation Required | No. | Usually required. |
| If the Result Is Positive | A follow-up colonoscopy is necessary. | Further management depends on the findings. |
Why Could This FDA Approval Be Important for India?
Although SimpleScreen CRC has been approved only in the United States, experts believe the concept of a blood-based colorectal cancer screening test could become relevant for countries such as India, where colorectal cancer is becoming an increasing public health concern (4✔ ✔Trusted Source
Temporal Trends of Colorectal Cancer Burden in India: A Nationwide and State-Level Analysis
).
According to a study, colorectal cancer is becoming an increasing public health concern in India. The researchers highlighted the need for stronger screening programs, greater awareness, and earlier diagnosis to reduce the growing disease burden.
Key findings from the study include:
- 69,409 new colorectal cancer cases were reported in 2021.
- The age-standardized incidence rate was 5.69 per 100,000, while the death rate was 4.60 per 100,000.
- Mizoram recorded the highest incidence of colorectal cancer.
- Gujarat showed the fastest increase in both incidence and mortality between 1990 and 2021.
- Behavioral risk factors accounted for the largest share of colorectal cancer deaths, while
high BMI (obesity) showed the steepest rise over the past three decades.
The study also noted that India lacks widespread population-based colorectal cancer screening programs.
Although SimpleScreen CRC is currently approved only in the United States, a convenient blood-based screening test could improve participation in early screening if it is validated and approved for routine use in India in the future.
According to the researchers, expanding screening access, promoting healthier lifestyles, and strengthening healthcare infrastructure will be crucial to reducing India’s colorectal cancer burden.
How Could This Technology Improve in the Future?
The currently approved SimpleScreen CRC test represents the first generation of Freenome’s blood-based colorectal cancer screening technology. According to findings presented at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, researchers have already developed an improved version of the assay.
The upgraded test combines enhanced DNA methylation analysis with an improved artificial intelligence algorithm to better detect cancer-related molecular signals (5✔ ✔Trusted Source
Clinical performance of an improved colorectal cancer (CRC) screening blood test.
In preliminary clinical evaluation involving 965 participants, the newer version demonstrated higher sensitivity for colorectal cancer while maintaining similar specificity.
Researchers also estimated that this next-generation version could potentially reduce colorectal cancer cases and deaths further if validated in larger studies and approved by regulators.
However, these findings are based on conference data, and the improved version of the test has not yet received FDA approval.
Frequently Asked Questions
Q: What is SimpleScreen CRC?
A: SimpleScreen CRC is an FDA-approved blood test that screens for colorectal cancer and certain advanced precancerous lesions.
Q: Who can take the new blood test?
A: It is intended for adults aged 45 years and older who are at average risk of colorectal cancer.
Q: How does the blood test detect colorectal cancer?
A: It analyses cell-free DNA and DNA methylation patterns in a blood sample using artificial intelligence to identify cancer-related signals.
Q: Can the blood test replace a colonoscopy?
A: No. A colonoscopy remains the gold standard because it can detect and remove precancerous polyps during the same procedure.
Q: What happens if the blood test result is positive?
A: A follow-up colonoscopy is recommended to confirm the findings and guide further care.
Q: How long does it take to receive the results?
A: Results are generally available within about two weeks after the blood sample is collected.
Q: Is SimpleScreen CRC available in India?
A: No. The test is currently approved in the United States and has not yet been approved for routine use in India.
References:
- FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S. – (https://www.freenome.com/newsroom/fda-approves-freenomes-simplescreen-crc/)
- Colorectal Cancer Screening Tests – (https://www.cancer.org/cancer/types/colon-rectal-cancer/detection-diagnosis-staging/screening-tests-used.html)
- Clinical Validation of a Circulating Tumor DNA–Based Blood Test to Screen for Colorectal Cancer – (https://jamanetwork.com/journals/jama/fullarticle/2834891?guestAccessKey=3fe13ce8-15cd-4e8f-a617-f36e453adcff)
- Temporal Trends of Colorectal Cancer Burden in India: A Nationwide and State-Level Analysis – (https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.71923)
- Clinical performance of an improved colorectal cancer (CRC) screening blood test. – (https://ascopubs.org/doi/10.1200/JCO.2026.44.2_suppl.22)
Source-Medindia